Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Cash from Financing Activities data on file, last reported at $19.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 86569.57% year-over-year to $19.9 million; the trailing twelve-month figure through Mar 2026 stood at $45.6 million (up 8746.71% YoY), and the FY2025 full-year result was $25.7 million, up 4917.15% from the prior year.
• Cash from Financing Activities fell to $19.9 million in Q1 2026, from $25.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $25.3 million in Q4 2025 to a low of -$202000.0 in Q2 2022.
• A 5-year average of $3.1 million and a median of $151000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 4140.0% in 2022 and surged 86569.57% in 2026, its largest moves.
• Tracing DSGN's Cash from Financing Activities over 5 years: stood at $130000.0 in 2022, then soared by 285.38% to $501000.0 in 2023, then tumbled by 47.5% to $263000.0 in 2024, then soared by 9526.24% to $25.3 million in 2025, then decreased by 21.26% to $19.9 million in 2026.
• Business Quant data shows DSGN's Cash from Financing Activities at $19.9 million in Q1 2026, $25.3 million in Q4 2025, and $37000.0 in Q3 2025.